id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-277739-eb4z3u66	Hu, Ke	Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial	2020-05-16		.txt	text/plain	3665	195	48	title: Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial In the latest publication, Lianhuaqingwen (LH) capsule (Shijiazhuang Yiling Pharmaceutical Co. Ltd., Shijiazhuang, China) was a manufactured product of the traditional Chinese medicine formula marketed in China that could significantly inhibit SARS-CoV-2 replication, alter the viral morphology and confer anti-inflammatory activity in vitro . On the basis of usual treatment, we sought to explore the safety and efficacy of LH capsules in patients with Covid-19 by conducting a multicenter randomized controlled trial in mainland China. Eligibility criteria consisted of the following: 1) Laboratory-confirmed cases with according to the Protocol for Diagnosis and Treatment of Novel Coronarvirus Pneumonia (4 th edition) which was issued by the National Health Commission (General Office Of The National Health And Health Commission, 2020) (Panel 1); 2) Being symptomatic (either having fever, coughing, or fatigue) plus radiologic abnormalities consistent with pneumonia; 3) Patients aged 18 years or greater of either sex.	./cache/cord-277739-eb4z3u66.txt	./txt/cord-277739-eb4z3u66.txt